Patents by Inventor Davide Pirolli

Davide Pirolli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11820758
    Abstract: The mitotic kinases regulating the dynamics of centrosomes and the functions of the mitotic spindle are potential targets for the antitumour therapy. In the present invention some molecules with inhibitory activity on NEK6 have been identified. The present invention relates to such molecules and to the compositions including them for use as inhibitors of NEK6 in a method of treatment of tumours both in monotherapy and in combinations with other drugs.
    Type: Grant
    Filed: April 2, 2019
    Date of Patent: November 21, 2023
    Assignees: CONSIGLIO NAZIONALE DELLE RICERCHE, MOLIPHARMA S.R.L.
    Inventors: Maria Cristina De Rosa, Davide Pirolli, Giovanni Scambia, Daniela Gallo, Marco Petrillo, Marta De Donato, Benedetta Righino
  • Publication number: 20210147395
    Abstract: The mitotic kinases regulating the dynamics of centrosomes and the functions of the mitotic spindle are potential targets for the antitumour therapy. In the present invention some molecules with inhibitory activity on NEK6 have been identified. The present invention relates to such molecules and to the compositions including them for use as inhibitors of NEK6 in a method of treatment of tumours both in monotherapy and in combinations with other drugs.
    Type: Application
    Filed: April 2, 2019
    Publication date: May 20, 2021
    Applicants: CONSIGLIO NAZIONALE DELLE RICERCHE, MOLIPHARMA S.R.L.
    Inventors: Maria Cristina DE ROSA, Davide PIROLLI, Giovanni SCAMBIA, Daniela GALLO, Marco PETRILLO, Marta DE DONATO, Benedetta RIGHINO
  • Patent number: 9994524
    Abstract: The T cells specific to human collagen type II, one of the possible autoantigens, have a crucial role in the development of rheumatoid arthritis in the context of HLA-DR4. The protein-protein interactions between the T cell receptor (TCR) and the type II collagen linked to the allele MHC of class II HLA-DR4 may thus represent the target for the development of new drugs against rheumatoid arthritis. Using computational virtual screening techniques, families of pharmacologically active molecules have been identified that interfere with the TCR/collagen II-MHCII interaction. The compounds identified here open up new possibilities in the treatment of rheumatoid arthritis.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: June 12, 2018
    Assignees: CONSIGLIO NAZIONALE DELLE RICERCHE, UNIVERSITÀ CATTOLICA DEL SACRO CUORE
    Inventors: Maria Cristina De Rosa, Francesco Ria, Bruno Giardina, Gianfranco Ferraccioli, Davide Pirolli, Chiara Nicolo′
  • Publication number: 20170204059
    Abstract: The T cells specific to human collagen type II, one of the possible autoantigens, have a crucial role in the development of rheumatoid arthritis in the context of HLA-DR4. The protein-protein interactions between the T cell receptor (TCR) and the type II collagen linked to the allele MHC of class II HLA-DR4 may thus represent the target for the development of new drugs against rheumatoid arthritis. Using computational virtual screening techniques, families of pharmacologically active molecules have been identified that interfere with the TCR/collagen II-MHCII interaction. The compounds identified here open up new possibilities in the treatment of rheumatoid arthritis.
    Type: Application
    Filed: March 24, 2017
    Publication date: July 20, 2017
    Inventors: Maria Cristina DE ROSA, Francesco RIA, Bruno GIARDINA, Gianfranco FERRACCIOLI, Davide PIROLLI, Chiara NICOLO'
  • Patent number: 9630954
    Abstract: The T cells specific to human collagen type II, one of the possible autoantigens, have a crucial role in the development of rheumatoid arthritis in the context of HLA-DR4. The protein-protein interactions between the T cell receptor (TCR) and the type II collagen linked to the allele MHC of class II HLA-DR4 may thus represent the target for the development of new drugs against rheumatoid arthritis. Using computational virtual screening techniques, families of pharmacologically active molecules have been identified that interfere with the TCR/collagen ll-MHCII interaction. The compounds identified here open up new possibilities in the treatment of rheumatoid arthritis.
    Type: Grant
    Filed: April 2, 2013
    Date of Patent: April 25, 2017
    Assignees: Consiglio Nazionale delle Ricerche, Università Cattolica del Sacro Cuore
    Inventors: Maria Cristina De Rosa, Francesco Ria, Bruno Giardina, Gianfranco Ferraccioli, Davide Pirolli, Chiara Nicolo′
  • Publication number: 20150073030
    Abstract: The T cells specific to human collagen type II, one of the possible autoantigens, have a crucial role in the development of rheumatoid arthritis in the context of HLA-DR4. The protein-protein interactions between the T cell receptor (TCR) and the type II collagen linked to the allele MHC of class II HLA-DR4 may thus represent the target for the development of new drugs against rheumatoid arthritis. Using computational virtual screening techniques, families of pharmacologically active molecules have been identified that interfere with the TCR/collagen ll-MHCII interaction. The compounds identified here open up new possibilities in the treatment of rheumatoid arthritis.
    Type: Application
    Filed: April 2, 2013
    Publication date: March 12, 2015
    Inventors: Maria Cristina De Rosa, Francesco Ria, Bruno Giardina, Gianfranco Ferraccioli, Davide Pirolli, Chiara Nicolo'